- Home
- RYN vs AXNX Comparison
RYN vs AXNX Comparison
Compare RYN & AXNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- AXNX
- Stock Information
- Founded
- RYN 1926
- AXNX 2012
- Country
- RYN United States
- AXNX United States
- Employees
- RYN N/A
- AXNX N/A
- Industry
- RYN Real Estate Investment Trusts
- AXNX Medical/Dental Instruments
- Sector
- RYN Real Estate
- AXNX Health Care
- Exchange
- RYN Nasdaq
- AXNX Nasdaq
- Market Cap
- RYN 4.5B
- AXNX 3.6B
- IPO Year
- RYN N/A
- AXNX N/A
- Fundamental
- Price
- RYN $30.26
- AXNX N/A
- Analyst Decision
- RYN Hold
- AXNX Hold
- Analyst Count
- RYN 3
- AXNX 8
- Target Price
- RYN $33.67
- AXNX $71.00
- AVG Volume (30 Days)
- RYN 706.7K
- AXNX 571.3K
- Earning Date
- RYN 11-06-2024
- AXNX 11-07-2024
- Dividend Yield
- RYN 3.75%
- AXNX N/A
- EPS Growth
- RYN 98.46
- AXNX N/A
- EPS
- RYN 1.07
- AXNX N/A
- Revenue
- RYN $1,004,107,000.00
- AXNX $431,902,000.00
- Revenue This Year
- RYN N/A
- AXNX $25.35
- Revenue Next Year
- RYN $4.02
- AXNX $19.92
- P/E Ratio
- RYN $28.45
- AXNX N/A
- Revenue Growth
- RYN 20.26
- AXNX 26.08
- 52 Week Low
- RYN $27.40
- AXNX $55.09
- 52 Week High
- RYN $35.29
- AXNX $71.05
- Technical
- Relative Strength Index (RSI)
- RYN 42.63
- AXNX 1.26
- Support Level
- RYN $29.71
- AXNX $70.37
- Resistance Level
- RYN $30.29
- AXNX $71.05
- Average True Range (ATR)
- RYN 0.71
- AXNX 0.15
- MACD
- RYN -0.06
- AXNX -8.31
- Stochastic Oscillator
- RYN 21.64
- AXNX 0.00
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About AXNX Axonics Inc.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.